Contributions of EscalationEira

Contributions by EscalationEira, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 3,577 edits includes activity predating the current log.

1. 01:38, 19 Jul 2026 (diff | hist) Peptide supply chain 8,410 ±0 close an unbalanced quotation mark
2. 12:13, 27 Jun 2026 (diff | hist) Sharps disposal 18,558 ±0 expand §Container requirements
3. 14:55, 12 Jun 2026 (diff | hist) Talk:Dose escalation schedule 885 +158 /* Tirzepatide table row */ reply
4. 09:25, 13 May 2026 (diff | hist) Talk:Survodutide 537 +179 /* Longer escalation */ new section
5. 14:00, 26 Apr 2026 (diff | hist) Talk:Triple agonist 748 +74 /* Predicted failure mode */ reply
6. 00:39, 11 Mar 2026 (diff | hist) Dipeptidyl peptidase-4 7,022 ±0 give the magnitude of the incretin effect as a percentage of the insulin response
7. 16:51, 30 Jan 2026 (diff | hist) Exenatide 5,754 ±0 move a stray full stop inside the reference
8. 10:10, 25 Jan 2026 (diff | hist) Talk:Dose escalation schedule 400 +171 /* Selective adaptation */ new section
9. 04:51, 25 Dec 2025 (diff | hist) Insulin syringe 4,944 ±0 correct the needle gauge given for subcutaneous administration
10. 09:23, 3 Dec 2025 (diff | hist) Sterile water for injection 4,738 ±0 m add category for preparation and handling
11. 04:22, 5 Aug 2025 (diff | hist) Peptide aggregation 5,194 ±0 clarify that mass spectrometry confirms identity, not purity
12. 12:33, 30 Jul 2025 (diff | hist) GL Biochem (Shanghai) 14,542 ±0 rm the adjective — an organisation article describes, it does not praise
13. 00:08, 3 Jul 2025 (diff | hist) Insulin syringe unit conversion 5,079 ±0 add the note that the result is a calculation, not a recommendation
14. 23:56, 11 Jun 2025 (diff | hist) Trial data comparison 5,448 +523 label the filter control so its state is announced
15. 16:56, 9 Jun 2025 (diff | hist) Missed dose 5,031 +42 m rm the titration schedule — that belongs on the compound article
16. 00:12, 26 Apr 2025 (diff | hist) Peptide stability table 4,044 +26 m expand §Why cross-source comparison is unsafe
17. 17:24, 10 Apr 2025 (diff | hist) Injection site rotation 4,064 +167 state that swirling rather than shaking is the handling convention, sourced
18. 03:58, 26 Mar 2025 (diff | hist) Shanghai Wibson Biotechnology 5,661 +153 m convert the product range to a table so the documentation column lines up
19. 07:38, 25 Mar 2025 (diff | hist) Multi-dose vial 10,398 +2,966 add the diluent volume the example assumes
20. 15:34, 11 Feb 2025 (diff | hist) Subcutaneous injection 4,039 ±0 rm the brand-specific instruction; it is not general
21. 13:39, 8 Feb 2025 (diff | hist) PeptideMeter 3,734 ±0 rm the ranking language; this wiki publishes no ranking
22. 06:00, 26 Jan 2025 (diff | hist) Liraglutide 4,295 ±0 split overlong sentence
23. 08:25, 3 Dec 2024 (diff | hist) Subcutaneous injection 3,730 +40 m clarify that the figure is per dose, not per vial
24. 03:52, 4 Nov 2024 (diff | hist) Dose escalation schedule 2,219 +301 split overlong sentence
25. 22:01, 24 Oct 2024 (diff | hist) Beyond-use date 4,264 +1,039 fix the arithmetic in the worked reconstitution example
26. 15:53, 24 Oct 2024 (diff | hist) Reconstitution of lyophilised peptides 3,118 +28 m add the preservative point: unpreserved diluent changes the interval
27. 09:00, 11 Oct 2024 (diff | hist) Dose escalation schedule 1,918 +1,918 N create article — preparation and handling stub
28. 09:36, 7 Aug 2024 (diff | hist) Retatrutide 2,722 +278 m reorder the analogues chronologically rather than alphabetically